Gapping up
In reaction to earnings/guidance:
- RAD +21.3%, BLBD +10.8%, ACN +7.1%, WPP +5.9% (guidance), LEN +3.1%, REVG +2.5% (guidance), SAFM +1.4%,
Other news:
- EOLS +19.3% (EOLS provides update on ITC ruling; Jeuveau sales and marketing continue under bond)
- MGNX +11.2% (receives FDA approval for MARGENZA for HER2-positive breast cancer)
- PROG +9.7% (announced that it is expanding the availability of COVID-19 RT-PCR testing across the United States to support the rising demand for testing)
- MTCR +9.1% (reports positive results from phase 1 trial of MET642)
- OTIC +7.9% (top-line results from phase 1/2 clinical trial of OTO-413 in patients with hearing loss)
- ROKU +6.5% (HBO Max to launch on Roku platform on Dec 17),
- ADMA +5.8% (adopts limited duration stockholder rights plan)
- HGEN +4.9% (announces completion of enrollment in Phase 1 Study of ifabotuzumab in glioblastoma multiforme)
- ATEC +4.6% (acquires EOS Imaging for $79.7 mln, plus retirement of debt)
- KVHI +4.5% (announces that ioCurrents has joined the KVH Watch Solution Partner program)
- NRZ +4.2% (increases dividend),
- NVAX +4.1% (signs agreement with New Zealand for 10.7 mln doses of COVID-19 vaccine)
- FREE +3.8% (to acquire all of the issued and outstanding capital stock of WSO Investments)
- PVG +3.6% (reports discovery at the Hanging Glacier Zone)
- SWBI +3.2% (authorizes $50 mln stock repurchase plan)
- SURF +3.2% (announces exclusive license agreement with GSK (GSK) for novel immunotherapy program)
- AZUL +2.9% (provides December and Q1 capacity outlook)
- MGEN +2.1% (enters into license agreement with Xencor for use of Xtend antibody technology for investigational antibodies to treat thyroid eye disease)
- PLNT +1.5% (new COO),
- RIO +1.5% (appoints Jakob Stausholm as chief executive, effective Jan 1)
- MGTX +1.4% (to present clinical update for AAV-hAQP1)
- SSNC +1.3% (to acquire Millennium Consulting Services and Millennium Seminar Services)
- ATCO +1.1% (prices Seaspan's $175 mln 3.75% exchangeable senior notes offering)
- ESGC +1% (stock offering)
- CDLX +1% (announces multi-year contract renewal with Lloyds Bank),
Analyst comments:
- ABUS +7.7% (initiation with Buy at H.C. Wainwright)
- MDB +6.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SI +5.1% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- OLN +4.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- DOMO +3.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SABR +3.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- RNG +3.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NBLX +2.6% (upgraded to Outperform from Neutral at Credit Suisse)
- FIVN +2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NNN +2% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- WMB +2% (upgraded to Outperform from Neutral at Credit Suisse)
- MSP +1.7% (upgraded to Overweight from Equal Weight at Barclays)
- WMG +1.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ILMN +1.2% (upgraded to Buy from Neutral at BTIG Research)
- NICE +1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CMA +0.9% (upgraded to Overweight from Equal-Weight at Stephens),